Compare MYND & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYND | BRNS |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 55.9M |
| IPO Year | 2017 | 2021 |
| Metric | MYND | BRNS |
|---|---|---|
| Price | $0.47 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 10.8K | ★ 70.5K |
| Earning Date | 08-27-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $209,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $0.45 | $0.64 |
| 52 Week High | $2.77 | $2.92 |
| Indicator | MYND | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 28.99 | 43.33 |
| Support Level | $0.50 | $0.68 |
| Resistance Level | $0.59 | $0.78 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 21.74 | 58.02 |
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.